Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,846 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,382 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 |
| clinicaltrials |
| NCT05200988 | Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC(Indi-Blade) | active not recruiting | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT06305832 | Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 102 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06297811 | Myeloprotection With Trilaciclib in Pan-cancer Population | not yet recruiting | Phase 2 | 132 | Sun Yat-sen UniversityOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 116 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06273553 | A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3 | not yet recruiting | Phase 1 / Phase 2 | 39 | RinuaGene Biotechnology Co., Ltd.INDUSTRY | 0 | Feb 22, 2024 | clinicaltrials |
| NCT06271551 | Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy(ESTRACISE) | not yet recruiting | Phase 2 | 310 | Central Finland Hospital DistrictOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT06259123 | Neoadjuvant PSMA-RLT in Oligometastatic PCa | recruiting | Phase 2 | 10 | Medical University of ViennaOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT06255964 | A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer | not yet recruiting | Phase 1 / Phase 2 | 236 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Feb 13, 2024 | clinicaltrials |
| NCT06251388 | A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer | recruiting | Phase 2 | 50 | West China Second University HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05983276 | Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer | recruiting | Phase 2 | 40 | Loyola UniversityOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT06249750 | Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer | recruiting | Phase 2 | 60 | Pengyuan LiuOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05753826 | Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer. | recruiting | Phase 2 | 37 | Fujian Cancer HospitalOTHER_GOV | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04176081 | Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate Cancer(SChLAP/IDC) | not yet recruiting | Phase 2 | 208 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06066216 | Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | not yet recruiting | Phase 2 | 45 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 23, 2024 | clinicaltrials |
| NCT06211790 | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma | recruiting | Phase 2 | 66 | Fudan UniversityOTHER | 1 | Jan 18, 2024 | clinicaltrials |
| NCT06209294 | Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery | recruiting | Phase 2 | 30 | Xiaohua WuOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT04716686 | Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05492123 | Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer | recruiting | Phase 2 | 112 | Hospital Israelita Albert EinsteinOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT05851547 | Dose Escalation For INtraprostatic LEsions(DEFINE) | recruiting | Phase 2 | 54 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04889742 | Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors(HETERERO) | not yet recruiting | Phase 2 | 110 | Charite University, Berlin, GermanyOTHER | 1 | Dec 26, 2023 | clinicaltrials |
| NCT04242017 | Long-term Better Than Short-term ADT With Salvage RT(LOBSTER) | recruiting | Phase 2 / Phase 3 | 394 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT06128460 | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. | not yet recruiting | Phase 2 | 24 | Obstetrics & Gynecology Hospital of Fudan UniversityOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT06149767 | Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer | not yet recruiting | Phase 2 | 26 | Fujian Cancer HospitalOTHER_GOV | 0 | Nov 29, 2023 | clinicaltrials |
| NCT03459820 | Prostate Cancer Patient Management With 18F-DCFPyL PET/CT | enrolling by invitation | Phase 2 / Phase 3 | 1,500 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT05961124 | Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer | recruiting | Phase 2 | 40 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03319628 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | active not recruiting | Phase 1 / Phase 2 | 523 | Mersana TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06129851 | Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer | not yet recruiting | Phase 2 | 90 | University of Kansas Medical CenterOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT06081595 | Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment | not yet recruiting | Phase 2 | 54 | Jin LiOTHER | 0 | Oct 13, 2023 | clinicaltrials |
| NCT06063070 | First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer | not yet recruiting | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Oct 2, 2023 | clinicaltrials |
| NCT06055738 | Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC | recruiting | Phase 2 | 20 | Tang-Du HospitalOTHER | 1 | Sep 28, 2023 | clinicaltrials |
| NCT03379909 | Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer(TROJAN) | recruiting | Phase 2 | 49 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT06039891 | Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer | not yet recruiting | Phase 2 | 55 | Peking Union Medical College HospitalOTHER | 0 | Sep 15, 2023 | clinicaltrials |
| NCT05511623 | Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical Cancer | recruiting | Phase 2 | 112 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05600127 | Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer(CHASIT) | recruiting | Phase 2 | 64 | Erasmus Medical CenterOTHER | 1 | Sep 8, 2023 | clinicaltrials |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | active not recruiting | Phase 2 | 46 | Roberto PiliOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05076942 | Groningen International Study on Sentinel Nodes in Vulvar Cancer-III(GROINSS-VIII) | recruiting | Phase 2 | 157 | University Medical Center GroningenOTHER | 2 | Aug 1, 2023 | clinicaltrials |
| NCT05794659 | Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer(Cornerstone4) | not yet recruiting | Phase 2 | 98 | Aston Sci. Inc.INDUSTRY | 1 | Jul 20, 2023 | clinicaltrials |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | recruiting | Phase 2 | 85 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 13, 2023 | clinicaltrials |
| NCT04654338 | 2 Ablative RadioTherapy Treatments for Prostate Cancer(EARTH) | recruiting | Phase 2 / Phase 3 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT04519151 | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer | recruiting | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Jun 8, 2023 | clinicaltrials |
| NCT04617756 | Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract(iNDUCT) | recruiting | Phase 2 | 50 | Centre Hospitalier Universitaire de NīmesOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05872724 | Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease) | recruiting | Phase 2 | 32 | Suzhou Municipal HospitalOTHER | 1 | May 24, 2023 | clinicaltrials |
| NCT04583254 | Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study | recruiting | Phase 2 | 48 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT05817903 | Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients(AxIn) | recruiting | Phase 2 | 118 | Consorzio OncotechOTHER | 1 | May 8, 2023 | clinicaltrials |
| NCT02881242 | Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer | active not recruiting | Phase 2 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT03275194 | HIPEC in Ovarian Carcinoma Clinical Stage IIIC and IV During Interval Laparotomy | recruiting | Phase 2 | 100 | Instituto Nacional de Cancerologia de MexicoOTHER | 1 | Apr 28, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Apr 2, 2024source: clinicaltrials